Document is current
Any future updates will be listed below
-
Authors
Huppert, Laura A.
Gliwa, Amelia S.
Tait, Madeline
Quintal, Laura
Starzinski, Stephanie
Cheung, Alexander
Moasser, Mark
Majure, Melanie
Melisko, Michelle
Munster, Pamela
Rugo, Hope S.
Campbell, Michael
Fong, Lawrence
Chien, A. Jo
- License Information
-
More Information
Article History
Received: 9 December 2024
Accepted: 9 October 2025
First Online: 21 November 2025
Competing interests
: Laura A. Huppert: Adboard/consulting: AstraZeneca, Pfizer. Research funding to institution: Genentech, Gilead, Greenwich LifeSciences, Johnson&Johnson, Mersana, Pfizer. Travel: Daiichi Sanko. Book royalties: McGraw Hill -Amelia S. Gliwa: No COI.-Madeline Tait: No COI.-Laura Quintal: No COI.-Stephanie Starzinski: No COI.-Alexander Cheung: No COI.-Mark Moasser: No COI.-Melanie C. Majure: No COI.-Michelle E. Melisko: For Myself: Research funding to institution: Pfizer, KCRN Research, Puma, OBI Pharma. For spouse: Speaker bureau/honoraria: Gilead, Astra Zeneca/Daichi-sankyo; Stock Ownership: Merrimack-Pamela Munster: No COI.-Hope S. Rugo: Institutional research support: AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Stemline Therapeutics, OBI Pharma; Ambryx. Consultancy/advisory: Chugai, Puma, Napo -Michael Campbell: No COI.-Lawrence Fong: Research support in the institution from Abbvie, Bavarian Nordic, Bristol-Myers Squibb, Dendreon, Janssen, Merck, Roche/Genentech; support as a consultant to Abbvie, Actym, Amgen, Astra Zeneca, Bioatla, Bristol Myer Squibb, Daiichi Sankyo, Immunogenesis, Innovent, Merck, Nutcracker, RAPT, Senti, Sutro, and Roche/Genentech; ownership interests in Actym, Bioatla, Immunogenesis, Nutcracker, RAPT, Senti, and Therapaint unrelated to the work here.-Amy Jo Chien: Research funding to institution from Merck, Puma, Amgen, Seagen, Pfizer, Olema. Advisory board: Genentech/Roche.
